WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies ...

Although the newsthat WuXi Bio sold its Ireland vaccine facility to Merck (MRK) for about $500M sent the stock lower, the firm thinks the company sold the facility not mainly due to “Biosecure ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

Then on Jan. 6, affiliated company WuXi Biologics said its subsidiary WuXi Vaccines plans to sell its vaccine plant in ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

China's WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom January 6, 2025 Drugmakers plan to raise U.S. prices on at least 250 branded medications including Pfizer COVID-19 ...

Merck (MRK) announced that the National Medical Products Administration of China approved Gardasil Vaccine for use in males 9-26 years of age ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to Merck for about $500 million. WuXi had previously said it was planning to sell some of its operations as the ...

WuXi 2269-1.25%decrease; red down pointing triangle Biologics agreed to sell an overseas vaccine facility to Merck MRK-1.32%decrease; red down pointing triangle & Co. for half a billion dollars ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate ...